CFTR Modulators: From Mechanism to Targeted Therapeutics.

doi:10.1007/164_2022_597

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

CFTR Modulators: From Mechanism to Targeted Therapeutics.

Handbook of experimental pharmacology - 1 Jan 2024

Yeh Han-I, Sutcliffe Katy J, Sheppard David N, Hwang Tzyh-Chang

Abstract excerpt

People with cystic fibrosis (CF) suffer from a multi-organ disorder caused by loss-of-function variants in the gene encoding the epithelial anion channel cystic fibrosis transmembrane conductance regulator (CFTR). Tremendous progress has been made in both basic and clinical sciences over the past three decades since the identification of the CFTR gene. Over 90% of people with CF now have access to therapies...

Topics

Humans
Cystic Fibrosis Transmembrane Conductance Regulator
Mutation
Cystic Fibrosis
Signal Transduction

Source

Open in PubMed

Identifiers

PMID: 35972584
DOI: 10.1007/164_2022_597

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics